Holen Sie sich die Stockscreener-App
0.406
4.61%
0.0179
Vorhandelsmarkt:
.39
-0.016
-3.94%
Schlusskurs vom Vortag:
$0.3881
Offen:
$0.3817
24-Stunden-Volumen:
5.44M
Relative Volume:
0.19
Marktkapitalisierung:
$10.94M
Einnahmen:
$94,000
Nettoeinkommen (Verlust:
$-13.28M
KGV:
-0.0556
EPS:
-7.2965
Netto-Cashflow:
$-11.67M
1W Leistung:
+0.74%
1M Leistung:
+60.47%
6M Leistung:
-70.55%
1J Leistung:
+328.25%
1-Tages-Spanne:
$0.3817
$0.4299
1-Wochen-Bereich:
$0.3669
$0.494
52-Wochen-Spanne:
$0.21
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.406 | 10.46M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech (AIM) seeks approvals to issue >19.99% shares, reverse split option - Stock Titan
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - The Manila Times
AIM Regains NYSE American Compliance After Equity-Boosting Financings - TradingView
AIM ImmunoTech (NYSE: AIM) lifts equity, regains NYSE American listing standards - Stock Titan
NYSE lifts compliance tag on AIM ImmunoTech after new equity financings - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million At-Market Financing to Advance Clinical Trials and Drug Development 1 - Minichart
AIM stock soars 42% as pancreatic cancer trial hits key enrollment milestone before schedule — CEO sees 'significant value-inflection period' ahead - MSN
AIM ImmunoTech Prices $1.3 Million Registered Direct Offering; Adds $5.3 Million Warrant Upside - TradingView
AIM ImmunoTech (NYSE: AIM) prices $2.65M stock and warrant financing deal - Stock Titan
$AIM ImmunoTech (AIM.US)$ - Moomoo
AIM ImmunoTech (AIM) shifts to majority-of-votes-cast rule for proposals - Stock Titan
[424B5] AIM ImmunoTech Inc. Prospectus Supplement (Debt Securities) - Stock Titan
AIM ImmunoTech announces $2.65M financing priced at market - MSN
symbol__ Stock Quote Price and Forecast - CNN
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech raises $2.65M in direct offering - Investing.com UK
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules - TradingView
AIM ImmunoTech raises $2.65M in direct offering By Investing.com - Investing.com Nigeria
AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement - marketscreener.com
AIM ImmunoTech Inc. Announces $2.65 Million Registered Direct Offering and Private Placement - Quiver Quantitative
AIM ImmunoTech Announces $2.65M Financing Priced At-Market Under NYSE Amer Rules - Moomoo
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules - GlobeNewswire
AIM ImmunoTech files prospectus for resale of 31.3 million shares - scanx.trade
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead - Stocktwits
AIM ImmunoTech (AIM) resale filing covers 31.3M shares and major dilution risk - Stock Titan
been making money off these waves yo in out in out $AIM ImmunoTech (AIM.US)$ - Moomoo
Pancreatic cancer trial sees 22.3‑month survival gain in select patients - Stock Titan
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ - GlobeNewswire
AIM ImmunoTech Highlights Ampligen’s Emerging Ebola Treatment Potential - TipRanks
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness - The Manila Times
AIM ImmunoTech Releases Video Discussing Ampligen's Potential in Addressing Ebola Outbreak Concerns and Unmet Therapeutic Needs - Quiver Quantitative
AIM ImmunoTech (AIM) showcases Ampligen’s Ebola preclinical data and preparedness focus - Stock Titan
Lethal Ebola strain, no vaccines: AIM video explores Ampligen's potential - Stock Titan
avg was .27 but I doubled and triple down at .70 went balls deep! trust your knowledge not your emotions!💯 - Moomoo
$AIM ImmunoTech (AIM.US)$ 🤷♂️ when market turns around we be all in. f it - Moomoo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$AIM ImmunoTech (AIM.US)$ on my dog ish!!! 🤑🤑 - Moomoo
$AIM ImmunoTech (AIM.US)$ will be back later for pullback :) - Moomoo
$AIM ImmunoTech (AIM.US)$ 🔥 💎 ✋️ - Moomoo
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):